Last €26.40 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:30 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

el.en. spa (ELN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - €26.86
52 Week Low
02/7/14 - €15.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EL.EN. SPA (ELN)

Related News

No related news articles were found.

el.en. spa (ELN) Related Businessweek News

No Related Businessweek News Found

el.en. spa (ELN) Details

EL.EN. Società per Azioni manufactures, researches and develops, distributes, and sells laser systems in Europe and internationally. The company offers laser equipment for use in various medical sectors, such as aesthetic, surgical, gynecological, otolaryngology, and odontostomatology; and lasers systems for applications in the field of cutting and welding plastic products, industrial cutting applications, and for the preservation and restoration of art works. It also provides industrial laser sources and systems for cutting, welding, marking, selective ablation, and engraving on metals, polymers, ceramics, and glass and natural products, such as wood and leather. In addition, it develops optical components and sub-assemblies for beam delivery, as well as offers after-sales services, including supplying of spare parts, and consulting and technical assistance. EL.EN. Società per Azioni was founded in 1981 and is headquartered in Calenzano, Italy.

Founded in 1981

el.en. spa (ELN) Top Compensated Officers

Managing Director, Executive Director, Direct...
Total Annual Compensation: €169.7K
Managing Director and Executive Director
Total Annual Compensation: €156.3K
Compensation as of Fiscal Year 2013.

el.en. spa (ELN) Key Developments

Cynosure, Inc. Signs Exclusive Agreement to Market MonaLisa Touch(TM) in North America for Gynecology Indications

Cynosure, Inc. announced that it has signed an exclusive agreement with El.En. S.p.A. to market and distribute in North America the MonaLisa Touch(TM), a carbon dioxide (CO(2)) laser for the treatment of vaginal atrophy, a condition that affects primarily postmenopausal women, breast cancer survivors and women who have undergone hysterectomies. Cynosure plans to introduce the MonaLisa Touch at the 2014 Pelvic Anatomy and Gynecologic Surgery Symposium (PAGS), which takes place next month in Las Vegas. The Company expects to begin selling the product in the U.S. in the first quarter of 2015 through a specialty surgical sales force. The MonaLisa Touch delivers short CO(2) ablative laser pulses to the vaginal wall, decreasing vaginal atrophy symptoms such as vaginal dryness, soreness and itching as well as painful urination and intercourse. The device received marketing clearance from the U.S. Food and Drug Administration in September 2014. Results of a recently published study of postmenopausal women who received three applications of the MonaLisa Touch laser over a 12-week period concluded that the device induced a significant improvement of vaginal atrophy symptoms. Recent clinical work also has been conducted to investigate the effects of the laser on sexual function and overall satisfaction with sexual life in postmenopausal women with vaginal atrophy. Treatment with the MonaLisa Touch is designed to reverse the deterioration of the vaginal walls associated with the loss of estrogen due to aging, hormonal treatments for breast cancer, and other conditions. The system is designed to stimulate and promote the regeneration of collagen fibers and the restoration of hydration and elasticity within the vaginal mucosa.

El.En. S.p.A. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Revenue Guidabce for the Full Year 2014

El.En. S.p.A. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, revenues were EUR 44.218 million against EUR 33.210 million a year ago. EBITDA was EUR 4.919 million against EUR 2.265 million a year ago. EBIT was EUR 4.048 million against EUR 1.102 million a year ago. Income before taxes was EUR 7.385 million against EUR 2.609 million a year ago. For the nine months, revenues were EUR 124.616 million against EUR 107.048 million a year ago. EBITDA was EUR 11.964 million against EUR 8.204 million a year ago. EBIT was EUR 10.532 million against EUR 4.835 million a year ago. Income before taxes was EUR 18.744 million against EUR 5.996 million a year ago. The results allow to establish for the full year 2014 a revenue growth target of 10%, improving the previously released 5% target.

EL.EN. Società per Azioni Presents at London Star Conference 2014, Oct-02-2014 through Oct-03-2014

EL.EN. Società per Azioni Presents at London Star Conference 2014, Oct-02-2014 through Oct-03-2014. Venue: London Stock Exchange, 10 Paternoster Square, London EC4M 7LS, United Kingdom. Presentation Date(s): Oct-02-2014. Oct-03-2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELN:IM €26.40 EUR 0.00

ELN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cutera Inc $9.90 USD -0.08
Syneron Medical Ltd $9.60 USD +0.07
Zeltiq Aesthetics Inc $28.48 USD -0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation ELN Industry Range
Price/Earnings 8.5x
Price/Sales 0.7x
Price/Book 0.9x
Price/Cash Flow 6.6x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EL.EN. SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at